Costly IVF Add-Ons Drain Bangladeshi Families as Lancet Study Questions Their Efficacy
Dhaka, Bangladesh - A Lancet Study has found that costly add-ons offered during IVF treatment rarely improve a patient's chances of having a baby, a finding with stark implications for Bangladeshi families already bearing severe financial strain. A journalist based in Dhaka shared with Dhaka Tribune that his wife has undergone IVF three times, with the couple spending nearly Tk20 lakh in total - yet they remain childless after a failed first cycle and a miscarriage in the second.
The account highlights a broader concern in Bangladesh, where Tk20 lakh represents an enormous economic burden for most families. Despite repeated cycles and mounting costs, the journalist's experience reflects what the Lancet Study suggests: that unproven add-ons marketed alongside standard IVF procedures may offer little tangible benefit while dramatically inflating treatment expenses. The case points to an urgent need for greater medical transparency from fertility providers and stronger regulatory oversight of the IVF sector in Bangladesh, to ensure that vulnerable families seeking parenthood are not misled into spending beyond their means on treatments lacking robust clinical evidence.
Further details are expected as the story develops
